Company Description
Metagenomi Therapeutics, Inc. a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases.
The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer.
Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in EmeryVille, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 9, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 124 |
| CEO | Jian Irish |
Contact Details
Address: 5959 Horton Street, 7th Floor EmeryVille, California 94608 United States | |
| Phone | 510 871 4880 |
| Website | metagenomi.co |
Stock Details
| Ticker Symbol | MGX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001785279 |
| CUSIP Number | 59102M104 |
| ISIN Number | US59102M1045 |
| Employer ID | 81-3909017 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jian Irish M.B.A., Ph.D. | Chief Executive Officer, President and Director |
| Dr. Brian Charles Thomas Ph.D. | Co-Founder and Director |
| Pamela M. Wapnick M.B.A. | Chief Financial Officer |
| Dr. Joseph Knowles M.D. | Co-Founder and Member of Scientific Advisory Board |
| Mark Leonard | Senior Vice President of Technical Development and Operations |
| Matthew L. Wein J.D. | General Counsel, Compliance Officer, Head of BD&L and Corporate Secretary |
| Dr. Alan Brooks Ph.D. | Senior Vice President of Research |
| Katalin Kauser M.D., Ph.D. | Senior Vice President of Translational Biology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 5, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2026 | 10-K | Annual Report |
| Mar 5, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 12, 2025 | 8-K | Current Report |
| Oct 1, 2025 | 8-K | Current Report |
| Sep 11, 2025 | 144 | Filing |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |